Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 IMD-Omega vs active control in mixed hyperlipidemia
KCT0009700Phase 3Recruiting
- Sponsor
- IMDPharm
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IMD-Omega in combined dyslipidaemia, hypertriglyceridemia, hypercholesterolemia and 1 more (2 arms), sponsored by IMDPharm. Started Jan 2024; status: recruiting.
02
Drugs
IMD-Omega
03
Conditions
combined dyslipidaemiahypertriglyceridemiahypercholesterolemiacardiac event risk
Beyond the preview
Go deeper on KCT0009700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009700.